Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exclusion Criteria

• •Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.
• •Patient has ever been treated with an approved or investigational GLP-1 receptor agonist.
• •Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.
• •Patient has a planned or anticipated revascularization procedure.
• •Pregnancy or planned pregnancy during the trial period.
• •Patient has end-stage renal disease or an estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m2.
• •Patient has a history of gastroparesis or pancreatitis.
• •Personal or family history of medullary thyroid cancer or MEN2 (Multiple EndocrineNeoplasia Type 2) or calcitonin level of \>40 ng/L at baseline.